TY - JOUR
T1 - Novel approaches for the rapid development of rationally designed arbovirus vaccines
AU - van Bree, Joyce W.M.
AU - Visser, Imke
AU - Duyvestyn, Jo M.
AU - Aguilar-Bretones, Muriel
AU - Marshall, Eleanor M.
AU - van Hemert, Martijn J.
AU - Pijlman, Gorben P.
AU - van Nierop, Gijsbert P.
AU - Kikkert, Marjolein
AU - Rockx, Barry H.G.
AU - Miesen, Pascal
AU - Fros, Jelke J.
N1 - Acknowledgements:
This work is part of the research programme One Health PACT with project number 109986 , which is (partly) financed by the Dutch Research Council (NWO) and has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 952373 .
Publisher Copyright: © 2023
PY - 2023/6
Y1 - 2023/6
N2 - Vector-borne diseases, including those transmitted by mosquitoes, account for more than 17% of infectious diseases worldwide. This number is expected to rise with an increased spread of vector mosquitoes and viruses due to climate change and man-made alterations to ecosystems. Among the most common, medically relevant mosquito-borne infections are those caused by arthropod-borne viruses (arboviruses), especially members of the genera Flavivirus and Alphavirus. Arbovirus infections can cause severe disease in humans, livestock and wildlife. Severe consequences from infections include congenital malformations as well as arthritogenic, haemorrhagic or neuroinvasive disease. Inactivated or live-attenuated vaccines (LAVs) are available for a small number of arboviruses; however there are no licensed vaccines for the majority of these infections. Here we discuss recent developments in pan-arbovirus LAV approaches, from site-directed attenuation strategies targeting conserved determinants of virulence to universal strategies that utilize genome-wide re-coding of viral genomes. In addition to these approaches, we discuss novel strategies targeting mosquito saliva proteins that play an important role in virus transmission and pathogenesis in vertebrate hosts. For rapid pre-clinical evaluations of novel arbovirus vaccine candidates, representative in vitro and in vivo experimental systems are required to assess the desired specific immune responses. Here we discuss promising models to study attenuation of neuroinvasion, neurovirulence and virus transmission, as well as antibody induction and potential for cross-reactivity. Investigating broadly applicable vaccination strategies to target the direct interface of the vertebrate host, the mosquito vector and the viral pathogen is a prime example of a One Health strategy to tackle human and animal diseases.
AB - Vector-borne diseases, including those transmitted by mosquitoes, account for more than 17% of infectious diseases worldwide. This number is expected to rise with an increased spread of vector mosquitoes and viruses due to climate change and man-made alterations to ecosystems. Among the most common, medically relevant mosquito-borne infections are those caused by arthropod-borne viruses (arboviruses), especially members of the genera Flavivirus and Alphavirus. Arbovirus infections can cause severe disease in humans, livestock and wildlife. Severe consequences from infections include congenital malformations as well as arthritogenic, haemorrhagic or neuroinvasive disease. Inactivated or live-attenuated vaccines (LAVs) are available for a small number of arboviruses; however there are no licensed vaccines for the majority of these infections. Here we discuss recent developments in pan-arbovirus LAV approaches, from site-directed attenuation strategies targeting conserved determinants of virulence to universal strategies that utilize genome-wide re-coding of viral genomes. In addition to these approaches, we discuss novel strategies targeting mosquito saliva proteins that play an important role in virus transmission and pathogenesis in vertebrate hosts. For rapid pre-clinical evaluations of novel arbovirus vaccine candidates, representative in vitro and in vivo experimental systems are required to assess the desired specific immune responses. Here we discuss promising models to study attenuation of neuroinvasion, neurovirulence and virus transmission, as well as antibody induction and potential for cross-reactivity. Investigating broadly applicable vaccination strategies to target the direct interface of the vertebrate host, the mosquito vector and the viral pathogen is a prime example of a One Health strategy to tackle human and animal diseases.
UR - http://www.scopus.com/inward/record.url?scp=85159305252&partnerID=8YFLogxK
U2 - 10.1016/j.onehlt.2023.100565
DO - 10.1016/j.onehlt.2023.100565
M3 - Article
C2 - 37363258
AN - SCOPUS:85159305252
SN - 2352-7714
VL - 16
JO - One Health
JF - One Health
M1 - 100565
ER -
